The Global Telmisartan Market, by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke,), by Composition (Single and Combinational), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), was valued at US$ 3,880.9 million in 2017, and is projected to exhibit a CAGR of 1.4% over the forecast period (2018 - 2026).

Telmisartan is a prescription medication often prescribed to relax and widen blood vessels in persons with high blood pressure. Telmisartan belongs to a group of drugs called angiotensin II receptor blockers (ARBs). Telmisartan may be used alone or in combination with other medications such as hydrochlorothiazide for treatment of high blood pressure. Increasing awareness regarding hypertension and its management by organizing global campaigns are expected to drive growth of the market. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) participated in global campaigns named May Measurement Month and World Hypertension Day for creating awareness among population related to blood pressure and their management.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2524

Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on ”Global Telmisartan Market" by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke), by Composition (Single and Combinational), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"

Key players are focused on development and launch of new generic product to maximize access to end users for their product in less cost, in turn gaining market share in telmisartan market. For instance, in June 2017, Solco Healthcare, announced its FDA approval for Telmisartan tablets, 20mg, 40mg, and 80mg, which are AB-rated equivalents to Micardis by Boehringer Ingelheim. Solco Healthcare will market Telmisartan tablets in 30 count bottles for all three strengths. Moreover, increasing government initiatives for hypertension management is expected to drive growth of the global Telmisartan market. For instance, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) launched, the India Hypertension Management Initiative (IHMI). The IHMI aims to reduce disability and death related to cardiovascular disease (CVD), by improving control over high blood pressure (hypertension), reducing salt consumption from food, and eliminating artificial trans-fats, which are leading risk factors for developing CVD.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/telmisartan-market-2524

Key Takeaways of the Telmisartan Market:

The global telmisartan market is expected to expand at a CAGR of 1.4% during the forecast period (2018 – 2026), owing to continuous marketing approvals for telmisartan.

Among strength, 80 mg segment is expected to hold leading position in the global telmisartan market, owing to approval from USFDA of telmisartan 80 mg in combination with other drugs. For instance, in September 2016, Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. received the manufacturing and marketing approval for Micatrio combination tablets from US FDA. Tablet comprises of telmisartan (concentration 80mg), amlodipine besylate, and hydrochlorothiazide (HCTZ). Such manufacturing and marketing approvals for telmisartan promote their growth in global market during the forecast period.

Major players operating in the global telmisartan market include C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2524

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737